--- a
+++ b/clusters/3009knumclusters/clust_191.txt
@@ -0,0 +1,993 @@
+Age >= 6 years at the NCI clinical center (>= 18 years at other participating sites)
+Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0 or 1\r\n* Use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
+Patient is at least 18 years of age
+Be ?18 years of age.
+Age ? 18 years at time of informed consent
+Parts A & C: patients must be >= 12 months and < 18 years of age at the time of study enrollment
+Parts B1-B6, B8, D1-D6, E3, E4: patients must be >= 12 months and =< 30 years of age at the time of study enrollment
+Part B7: patients must be >= 12 months and < 18 years of age at the time of study enrollment
+Age 50.0-75.0 years.
+Must be ? 18 years of age.
+Age ? 10 years
+Age of 18 years or older; in addition, patients age 12 to 17 years may enroll beginning in Cohort 2 if weight ? 40 kg
+A serum creatinine based on age/gender as follows:\r\n* =< 0.6 mg/dL (patients age 1 to < 2 years)\r\n* =< 0.8 mg/dL (patients age 2 to < 6 years)\r\n* =< 1 mg/dL (patients age 6 to < 10 years)\r\n* =< 1.2 mg/dL (patients age 10 to < 13 years)\r\n* =< 1.4 mg/dL (female patients age >= 13 years)\r\n* =< 1.5 mg/dL (male patients age 13 to < 16 years)\r\n* =< 1.7 mg/dL (male patients age >= 16 years)
+Patients with body mass index (BMI) < 3rd percentile for age, as defined by WHO criteria for patients 1-2 years of age and Centers for Disease Control and Prevention (CDC) criteria for patients > 2 years of age, are not eligible
+Participants who are less than 10 years of age at start of maintenance chemotherapy
+Part A1: Patients must be >= 12 months and =< 21 years of age at the time of study enrollment
+Standard risk 1: Patient must be < 11 years of age at enrollment
+Standard risk 2: Patients must be >= 11 and < 25 years of age at enrollment
+Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
+Hemoglobin >= 8 g/dL for patients =< 16 years of age; >= 9 g/dL for patients > 16 years of age; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibility
+Efficacy Phase: Patients must be =< 40 years of age at the time of enrollment
+Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
+Patients must be >= 18 years of age
+Age >= 14 years (>= 18 years in Germany)
+Age ?18 years (or per national guidelines).
+Age 18 years or above
+Subjects must be age ? 21 years at initial diagnosis
+? 18 years of age
+Age ? 18 years.
+Age ?18 years.
+Subject is at least 18 years of age.
+Age >= 18 years.
+Subjects must be age ? 21 years at initial diagnosis
+Men and women ?18 years of age
+Adults (Age ? 18 years)
+Subjects must be ?18 years of age.
+Male or females with an age ? 18 years.
+Age ? 18
+Age ? 18 years of age
+Be > 18 years of age on day of signing informed consent
+Age >/=18 years at the time the ICF is signed
+Age . 18 years old at the time of signing the informed consent
+Age >/= 18 years;
+Age > 18 years.
+Subjects ? 18 years of age.
+Age: 18 years
+Patients must be ?18 years of age
+At least 18 years of age
+Age ?18 (or age ? 20 of age as required by local regulation).
+? 18 years of age
+Adults age 18-80 years
+Age >21 years
+Age > or = 21 years
+?18 years of age
+Age ? 18 years
+COHORT 1: Be >= 18 years of age on day of signing informed consent
+COHORT 2: Be >= 65 years of age on day of signing informed consent
+18 years of age or order
+Subject is at least 18 years of age.
+Age ? 15 and < 41 years
+Be > 6 months and < 18 years of age
+Age ?18 years
+Age ?18 years.
+Age ? 18 years.
+Patients age ?18 years at signing the informed consent.
+Must be ? 18 years of age at the time of signing the ICF.
+Age ? 18 years
+Subjects ?18 years of age for solid tumor; in the case of midline carcinoma with NUT rearrangement. subjects may be ?16 years of age.
+Patients must fit into one of the following categories:\r\n* Age >= 18 years to < 60 years with a cumulative illness rating scale (CIRS) score >= 6 OR deemed ineligible for cytotoxic chemotherapy by the treating investigator\r\n* >= 60 years
+Age ?18 years
+Age>= 50
+Men and women ? 18 years of age.
+Lansky >= 50% for patients =< 10 years of age or Karnofsky >= 50% for patients > 10 years of age
+Age above or equal to 18 years
+Pts must be ? 18 years of age
+Must be less than 30 years of age at time of original diagnosis
+Karnofsky >= 50% for patients > 10 years of age
+Age >18 years.
+?18 years of age.
+Age > 18 years.
+Be ?18 years of age.
+Adequate performance status: Lansky ? 50 for patients < 16 years of age
+Men and women ? 18 years of age.
+Ambulatory and ?18 years of age.
+?18 years of age.
+Patients age ?18 years at signing the informed consent.
+At least 18 years of age at the time of signing the informed consent form.
+Post-menopausal (>= 60 years of age or with follicle stimulating hormone [FSH] > 30 IU/L if age 50-59)
+Age ?18 years
+Age >18 years and ?75 years.
+Age ?60 years; or
+Subjects > 10 years of age: Karnofsky >= 50%; Subjects =< 10 years of age: Lansky scale >= 50%
+St. Jude patients must be between 2 years and =< 21 years of age, on therapy (active patient), or within 3 years of completion of therapy; patients treated at collaborating sites must be =< 24 years old
+Male or female participants age ?18 years (or any age ?18 years if that age is considered to be an adult per the local jurisdiction) at the time of informed consent
+? 18, but < 75 years of age
+Age >/= 18 years
+INCLUSION - PROCUREMENT: The first six (6) patients treated on the study should be adults (? 18 years [yrs] of age); six adolescents (age 12-18) should be treated before children (? 3 yrs of age) are eligible
+18 years of age at the time of consenting.
+Age ?18 years .
+Patients ?12 years of age
+Subjects must be at least 1 and less than or equal to 18 years of age at the time of study entry.
+Age >= 21 years
+Age ? 18 years
+Age ? 18.0 years and < 66.0 years at the time of enrollment.
+Patients =< 25 years of age will be eligible for the pre-surgical cohort; patients between 18-25 years of age will be treated at the adult Food and Drug Administration (FDA)-approved dose of 960 mg BID and can be enrolled immediately; patients less than 18 years of age will be enrolled and treated at the pediatric MTD once it is defined in the safety cohort
+Patients =< 25 years of age with evaluable disease will be eligible for the expansion cohort; patients between 18 and 25 years of age will take adult dose of 960 mg BID and are eligible at the initiation of the trial; patients less than 18 years of age will take the MTD once it is defined in the safety cohort
+Between 6 months and <18 years of age (or between 3 years and <18 years of age for rrcHL participants) on day of signing informed consent/assent (the first 3 participants dosed in Part 1 are to be ? 6 years of age)
+Lansky Play Scale ?50 for participants from 6 months up to and including 16 years of age; or Karnofsky score ?50 for participants >16 years of age
+Age ?18 years old
+Male or female patients age ? 18 years of age at the time of informed consent
+Age ? 18 years.
+Subject is ?18 years of age at the time of signing the study informed consent.
+Age at least 18 years.
+Is of age ? 18 years
+Male or female, ?18 years of age (?20 years of age in Taiwan)
+Patient is < 75 years of age at time of enrollment.
+? 18 years of age
+Age ? 18 years.
+Age > 18 years
+Men and women at least 18 years of age
+Age ? 18.
+Children under the age of 18
+Participants with 1 to less than (<) 18 years of age (Part 1 only), or 1 to 30 years of age, inclusive, if initial diagnosis of mature B-cell non-Hodgkin lymphoma (NHL) occurred at <18 years of age (Part 2 only)
+?18 years of age.
+Patients must be ? 45 years of age
+Age ? 18 years.
+Must be ? 18 years of age at the time of signing the ICF.
+Age: ? 21 years at the time of study entry.
+Age between 18 and 70 years (both inclusive).
+? 18 years of age
+Age >= 18 years or age of majority at the participating site, whichever is greater
+Age ?18 years.
+Age +/> 70
+?18 years of age.
+Age ?18 years and ?80.
+Subject is > 22 years of age.
+? 18 years of age.
+Patients must be less than 18 years of age at the time of diagnosis.
+Normal cardiac stress test for patients over 50 years of age
+45 years of age or less.
+Age ?18 years. Because no dosing or adverse event data are currently available on the use of ipilimumab or indoximod in patients <18 years of age, children are excluded from this study.
+Age > 18 years
+DONOR: age >= 12 and =< 75 years
+Must be > = 18 years of age.
+Age ? 12 months and < 18 years
+Age >/= to 18 years
+Must be at least 18 years of age.
+Subjects must have a performance status of > 50%; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
+Age ?18 years
+Because no dosing or adverse event data are currently available on the use of enzalutamide and CRLX101 in patients < 18 years of age and prostate cancer is not common in children < 18 years of age, children are excluded from this study.
+Age ? 18 years
+? 18 years of age
+Age ?18 years on the day of signing informed consent.
+Patients who are ? 18 years of age.
+Age ? 18 years
+Age >18 years
+At least 18 years of age.
+Age >= 1 year and < 25 years at the time of screening; exception: participants with recurrent, progressive, or refractory medulloblastoma and are >= 1 and < 40 years of age at the time of study screening are eligible for screening
+STRATUM A: Age >= 1 year and < 25 years at the time of screening
+STRATUM B: Age >= 1 year and < 25 years at the time of study enrollment
+STRATUM C: Age >= 10 years and < 40 years at the time of study enrollment
+Men and women of age ?18 years.
+Age ? 18 years.
+Age ? 18 years
+Men and women of age ?18 years.
+2 to less than 19 years of age.
+Karnofsky ? 50 for patients ? 16 years of age, and Lansky ? 50 for patients < 16 years of age.
+Platelet count ? 100,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment). Renal Function: • Creatinine clearance or radioisotope glomerular filtration rate (GFR) ? 70mL/min/1.73 m2 or normal serum creatinine based on age as shown below or GFR > 70ml/min/1.73m^2: Age < 5 years: 0.8 mg/dL maximum Age 5 to < 10 years: 1.0 mg/dL maximum Age 10 to < 15 years: 1.2 mg/dL maximum Age > 15 years: 1.5 mg/dL maximum Liver Function:
+Age ?18 years at the time of informed consent.
+At least 18 years of age
+Age ? 18 years old at the time of signing the informed consent
+Patient is at least 18 years of age.
+Age >=18 years at time of signing Informed Consent Form
+Age >18 years and ? 70 years at the time of enrollment
+Subjects must ?18 years of age
+At least 18 years of age.
+Participant must be >= 18 years of age.
+0 to 2 for Participants >= 75 years of age or
+0 to 3 for Participants >= 18 to 74 years of age.
+Age > 55 years with no menses for 12 or more months without an alternative medical cause.
+Age ?12 years old
+The participant has a Lansky (<16 years of age) or Karnofsky (?16 years of age) performance score of at least 50.
+Patients must be ? 18 years of age.
+Age ?18 years
+Patient must be > 18 years of age.
+Patient must be ?1 year and <75 years of age at screening and undergoing allogeneic HSCT.
+? 12 years of age
+Age ? 18 years.
+Be ? 18 years of age on day of signing informed consent.
+Donor age >= 18 years
+Men over 18 years of age.
+Age ?18 years at the time of signing informed consent.
+Age >= 18 years
+Age ?18 years
+Age >21 years
+0 for (age <61 years), +2 for (age 61-70 years), +4 for (age >71 years).
+Age >75.
+Age ? 18 years
+Be ? 18 years of age at time of consent
+Patient is at least 18 years of age and <90 years of age at the time Informed Consent is signed.
+Karnofsky > 50 for patients > 16 years of age and Lansky > 50 for patients =< 16 years of age
+Age ?18 years
+be ?18 years of age;
+Patients must be ? 18 years of age.
+Age ? 18 years
+Eastern Cooperative Oncology Group (ECOG) performance status =< 2 or Karnofsky >= 60% in patients > 16 years of age, Lansky >= 60 for patients =< 16 years of age
+Age ?18 years at the time of informed consent
+At least 18 years of age.
+Patients >= 18 years of age with relapsed/refractory Ph-positive ALL.
+Age ?18 years.
+Subject is ?18 years of age at the time of signing the study informed consent.
+The pediatric cohort is defined as age younger than 18 years.
+Age 18 or more years
+At least 18 years of age.
+Age ? 18 years at the time of consent.
+Females ?18 years of age
+Age ?18 years;
+Subjects ? 18 years of age at screening
+? 75 years of age OR
+of 0 to 2 for participants ? 75 years of age or
+of 0 to 3 for participants between 18 to 74 years of age.
+Age > 55 years with no menses for 12 or more months without an alternative medical cause.
+DONOR: At least 18 years of age
+Age 27- 69 at enrollment
+Age 12 to 65 years
+Patients must be at least 18 years of age
+Patient is at least 18 years of age
+At least 18 years of age.
+Patients must be at least 18 years of age.
+ECOG Performance Status (PS) of 0, 1 or 2. For newly diagnosed AML patients < 75 years of age, ECOG 0-3; for ? 75 years of age, ECOG 0-2.
+Age ?18 years
+Men and women, ? 65 years of age.
+Minimal limitation on activities of daily living as measured by Karnofsky ? 50 for participants > 16 years of age or Lansky ? 50 for participants ? 16 years of age.
+Age: Male or female age ? 2 years and < 22 years unless enrolled in Part E
+Subject is ?18 years of age
+DONOR: Age > 14 years
+?18 years of age
+Patients ?18 years of age at the time of signature of the ICF
+Age 40 years or older; this age cutoff is justified because breast cancers in women under the age of 40 are known to have a significantly higher risk of IBTR presumably due to underlying biologic differences
+Age:\r\n* Phase 1: >= 6 and =< 21 years of age at time of enrollment\r\n* Phase 2: >= 6 and =< 21 years of age at diagnosis
+Minimum age of 18 years
+Adults ?18 years of age
+Age ? 18 years.
+Age > 18 years.
+Age ? 18 years old (? 20 years old in Japan);
+Age ?18 years
+Age ?18 years
+DONOR: At least 18 years of age
+Adults ?18 years of age
+Age ? 16 years
+Patient age criteria: age >= 18 and =< 45 years (myeloablative regimen 1; age >= 18 and =< 80 years (nonmyeloablative regimen 2) at the discretion of the investigator(s); age >= 18 and =< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy may receive reduced intensity regimen 3
+< 70 years of age with no matched 5/6 or 6/6 sibling donor - patients >= 70 and =< 75 years of age may be eligible if they have a co-morbidity score =< 2
+Age > 18
+Age ?18 years at the screening visit.
+Age 18 or more years
+Post-menopausal defined as\r\n* Age >= 55 years and 1 year or more of amenorrhea\r\n* Age < 55 years and 1 year or more of amenorrhea with an estradiol assay < 20 pg/mL\r\n* Surgical menopause with bilateral oophorectomy
+Age * 18 years
+DONOR: Age >= 18 and =< 70 years
+DONOR: Age 18 to 70 years of age
+Appropriate written consent – adult or parent/guardian if patient is < 18 years of age and minor information sheet if patient is > 8 years of age
+Age >= 40 to < 75 years; patients 18 to 39 years of age will be eligible only if the investigator has determined that the patient has comorbidity(ies) precluding conventional allogeneic transplantation with full intensity myeloablative conditioning
+Be 18 years of age on day of signing informed consent.
+Patient is between 18 and 75 years of age, inclusive.
+Male > 18 years of age
+Performance status < 90% in patients 70 years old or greater, < 80% in patients less than age 70 years
+Karnofsky performance status >= 50% for patients > 16 years of age, or Lansky performance status >= 50% for patients =< 16 years of age.
+Age ? 18 years.
+Age 6 months - 29.99 years at enrollment
+be over age 18
+?18 years of age
+Age (at the time of consent/assent): ?16 years of age
+Female subjects who are at least 18 years of age at the time of informed consent
+Patient must have Karnofsky >= 60% for patients > 10 years of age; Lansky Play Scale >= 60 for children =< 10 years of age
+Patients must have a performance status of 0, 1 or 2; use Karnofsky >= 60 for patients > 16 years of age and Lansky >= 60 for patients =< 16 years of age
+< 30% for patients < 60 years,
+At least 18 years of age.
+DONOR: Age =< 60 years of age
+Age ?18 years
+Adequate renal function as evidenced by: a) Serum creatinine based on age/gender as below. If serum creatinine is greater than maximum serum creatinine for age/gender as shown in the table below, then creatinine clearance (or radioisotope glomerular filtration rate [GFR]) must be greater than 70 milliliter/minute/1.73 square meter (mL/min/1.73 m2). Maximum Serum Creatinine in milligrams/deciliter (mg/dL) for male: i. Age 2 to less than 6 years = 0.8 ii. Age 6 to less than 10 years = 1.0 iii. Age 10 to less than 13 years = 1.2 iv. Age 13 to less than 16 years = 1.5 v. Age greater than or equal to 16 years = 1.7 Maximum Serum Creatinine (mg/dL) for Female: vi. Age 2 to less than 6 years = 0.8 vii. Age 6 to less than 10 years = 1.0 viii. Age 10 to less than 13 years = 1.2 ix. Age 13 to less than 16 years = 1.4 x. Age greater than or equal to 16 years = 1.4 The threshold creatinine values in this Table were derived from the Schwartz formula for estimating glomerular filtration rate using child length and stature data published by the CDC. b) Urine dipstick less than 2+ for proteinuria. Participants who have greater than or equal to 2+ proteinuria on dipstick urinalysis should undergo a spot protein-creatinine (P/C) ratio that should be Grade less than 2. c) No clinical evidence of nephrotic syndrome.
+? 18 years of age.
+DONOR: Must be 18-80 years of age, inclusive
+Age > 18 years at time of study entry
+Performance status: Karnofsky >= 50 for patients > 16 years of age; Lansky >= 50 for patients =< 16 years of age
+Age ? 80 years
+Age < 80 years and at least 1 of the following conditions:
+Patients must have a performance status of >= 70; (Karnofsky if > 16 years and Lansky if =< 16 years of age)
+Patients must be > than 12 months and ? 21 years of age at the time of study enrollment.
+Karnofsky ? 50% for patients > 16 years of age and Lansky ? 50 for patients ? 16 years of age.
+Patients age 18 to 70 years old; eligibility for pediatric patients will be determined in conjunction with an MD Anderson Cancer Center (MDACC) pediatrician; patients age 2-17 years may be enrolled after at least 10 adults (ages 18-70 years old) have been assessed for safety at day 30
+Are at least age 18 at screening (Visit 1)
+Patient must be > 18 years
+Age < 60 years
+DONOR: Age >= 18 years
+Age-adjusted serum creatinine < 1.5 x normal for age
+Age: ? 21 years at the time of diagnosis.
+There are no age restrictions
+Any patient with both metastatic ependymoma and age < 3 years at the time of enrollment
+Age <18-years-old.
+Age 12 months to <21 years
+Age ? 50
+At least 18 years of age
+Patient is < 18 years of age
+For Phase I Only: Age >/=18 years
+MATCHED RELATED DONOR: Age less than 6 years or greater than 70 years
+Age: up to and including 18 years at diagnosis of Haemophagocytic Lymphohistiocytosis
+DONOR: At least 18 years of age
+DONOR: Age >= 0.5 years
+Patients must have a performance status of >= 70; (Karnofsky if > 16 years and Lansky if =< 16 years of age
+Must be > = 50 years of age.
+Age > or = 15 years
+Age ? 18 years
+Men and women patients 18 years of age and up
+Age > 18
+Age at least 18 years.
+Must be 2 - 45 years of age and at least 10 kg
+Age between 18 and 75 years, inclusive.
+Age ? 18 years
+Group B: Individuals > 70 years of age with previously untreated AML or individuals < 70 years of age with previously untreated AML who refuse or are unable to receive cytarabine as determined by the treating physician
+Patients must have a Lansky performance status of >= 30 for children =< 10 years of age or a Karnofsky performance status of > 30 for children > 10 years of age
+Patients must have adequate renal function defined as < 1.5 x normal serum creatinine as adjusted for age:\r\n* 0.8 mg/dl for < 5 years of age\r\n* 1.0 mg/dL for > 5 and < 10 years of age\r\n* 1.2 mg/dL for > 10 and < 15 years of age\r\n* 1.5 mg/dL for > 15 years of age\r\n* Or a calculated or measured creatinine clearance or radioisotope glomerular filtration rate (GFR) > 70 ml/min/1.73m^2 obtained within 14 days prior to registration
+Age: \r\n* Stratum I (TMI containing arm): 18-60 years of age\r\n* Stratum II (non TMI arm): 18-70 years of age
+Patients must have a performance status of >= 70; (Karnofsky if > 16 years and Lansky if < 16 years of age)
+DONOR: Age >= 12 years
+DONOR: Age >= 12 years of age
+Age > 16 years.
+Age ?18 years at the time of signing the informed consent form.
+Performance status: Karnofsky >= 80% (subjects >= 16 years of age); Lansky >= 80% (for subjects 10-15 years of age)
+Aged =< 3 years at diagnosis (not age of transplant)
+Must be < 70 years old with no matched 5/6 or 6/6 sibling donor; patients >= 70 and =< 75 years of age may be eligible if they have a co-morbidity score =< 2
+Patients must be >18 years of age.
+At least 18 years of age
+Participants must be > 18 years of age
+Age ? 18 years old.
+Performance level: Lansky ? 50% for patients ? 16 years of age and Karnofsky ? 50% for patients > 16 years of age.
+Age: ?12 months to <18 years old at the time of informed consent
+Age ?18 years;
+Performance status greater than or equal to (>=) 70 by Lansky scale (for participants less than [<] 16 years of age) or Karnofsky scale (for participants [>=] 16 years of age)
+within the last 5 years OR
+Patients <18 years of age
+Postmenopausal defined as women >54 years of age with amenorrhea for ? 2 years prior to screening
+Age of at least 18 years.
+Men and women, ? 18 years of age
+>18 years
+Age ? 18 years at the time of screening or age of consent according to local law
+age <18 years;
+Between 18 and 80 years of age inclusive, at the time of signing the informed consent.
+Age ?18 years at the screening visit.
+Be > 18 years of age on day of signing informed consent.
+Age 55 years and 1 year or more of amenorrhea
+Age ? 18 years.
+At least 18 years of age.
+Age 18-76 years
+Post- menopausal female patients, 18 years of age or greater.
+Age >18 years of age; male or female.
+Age ? 18 years
+At least 18 years of age
+Patients must be >_18 years of age
+Patients must be age >/= 18 years.
+Age >/= 18 years.
+At least 18 years of age
+At least 18 years of age
+At least 18 years of age
+Age > 18 years. Because no dosing or adverse event data are currently available on the use of AR-67 in patients < 18 years of age, children are excluded from this study but will be eligible for future pediatric single-agent trials, if applicable.
+Age ? 18 years with HCT comorbidity index < 3
+At least 18 years of age.
+Age >18 years
+Man or woman, age >18 years
+Age > 18 years
+Age ?18 years;
+Patients must be 18 years of age.
+Age > = 18 years of age
+Age < 18 years of age
+Age >18 years
+Age between 18 and 70 years, inclusive.
+Females at least 18 years of age
+Age ? 18 years at time of signing informed consent form.
+Stratum 1 (IDH wild-type): Patients must be >= 3 years of age and =< 21 years of age at the time of enrollment
+Stratum 2 (IDH mutant): Patients must be >= 3 years of age and =< 25 years of age at the time of enrollment
+Minimum age 18 years (in Japan, minimum age 20 years).
+Age ?18 years at the time of consent.
+Patients must be at least 18 years of age.
+Age >/= 12 years
+Age ? 2 years.
+Age greater than 18 years.
+Age ? 18 years old
+Age ? 18 years and ? 60 years
+Age ? 18 years and ? 75 years
+Age >18 years;
+PRE-REGISTRATION: Performance level as measured by Karnofsky >= 60% for patients > 16 years of age or Lansky >= 60% for patients =< 16 years of age.
+ENROLLMENT: Performance level as measured by Karnofsky >= 60% for patients > 16 years of age or Lansky >= 60% for patients =< 16 years of age.
+ENROLLMENT: Creatinine clearance >= 60 mL/min/1.73m^2 (calculated by 24 hour [h] urine collection or nuclear glomerular filtration rate [GFR] scan if 24 h collection is not possible) or a serum creatinine based on age and gender as follows: age 1 month to < 6 months, maximum serum creatinine (mg/dL) male 0.4, female 0.4; 6 months to < 1 year, 0.5, 0.5; 1 to < 2 years, 0.6, 0.6; 2 to < 6 years, 0.8, 0.8; 6 to < 10 years, 1, 1; 10 to < 13 years, 1.2, 1.2; 13 to < 16 years, 1.5, 1.4; >= 16 years, 1.7, 1.4.
+Be ? 18 years of age.
+Age ?60 or
+Age ? 18 years.
+The subject must be >= 12 years of age at the time of consent
+Age ? 18 years
+Age ? 18 years old.
+Age >/= 60 years
+Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
+Age (must have body surface area [BSA] >= 0.55 m^2):\r\n* Phase I: >= 3 and =< 21 years of age\r\n* Phase II: >= 3 and =< 35 years of age
+Age ?18 years.
+Age > 18 years
+DONOR: Age >= 18 to =< 77 years old
+DONOR: Age >= 13 years old (yo) and =< 75 years
+DONOR: Age less than 18 years
+Patients must have a Karnofsky performance level of >= 30 for patients > 16 years of age or a Lansky performance scale of >= 30 for patients =< 16 years of age and life expectancy > 8 weeks
+Participants must be ? 18 years of age.
+> 85 years of age must be approved by principal investigator
+Age ?18 years
+Minimum Age 18 years (in certain territories, the minimum age requirement may be\n             higher eg age 20 years in Japan and Taiwan)
+Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
+Creatinine clearance OR radioisotope glomerular filtration rate >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:\r\n* 0.4 mg/dL (1 month to < 6 months of age)\r\n* 0.5 mg/dL (6 months to < 1 year of age)\r\n* 0.6 mg/dL (1 years to < 2 years of age)\r\n* 0.8 mg/dL (2 years to < 6 years of age)\r\n* 1.0 mg/dL (6 years to < 10 years of age)\r\n* 1.2 mg/dL (10 years to < 13 years of age)\r\n* 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 years to < 16 years of age)\r\n* 1.7 mg/dL (male) or 1.4 mg/dL (female) (>= 16 years of age)
+DONOR: 14-75 years of age
+Age:\r\n* Part A1: Patients must be >= 12 months and < 18 years of age at the time of study enrollment\r\n* Part A2: Patients must be > 6 months and < 12 months of age at the time of study enrollment; patients will enroll one dose level behind the dose level at which patients in Part A1 are enrolling
+Age:\r\n* Phase 1 (Part A)\r\n** Patients must be > than 12 months and =< 21 years of age at the time of study enrollment\r\n* Phase 2 (Part B and Part C)\r\n** Patients must be > than 12 months and =< 30 years of age at the time of study enrollment
+ECOG 0, 1 or 2, or for children =< 10 years of age, Lansky >= 60
+Greater than age-adjusted normal serum creatinine (see below) and a creatinine clearance < 60 mL/min/1.73 m^2\r\n* =< 0.8 mg/dL (age =< 5 years)\r\n* =< 1.0 mg/dL (5 years < age =< 10 years)\r\n* =< 1.2 mg/dL (age > 10 years)
+Creatinine below age-adjusted maximum limits in the table below OR creatinine clearance >= 60 mL/min/1.73 m^2 assessed within seven (7) days prior to the start of therapy\r\n* 0.8 mg/dl (patients =< 5 years of age)\r\n* 1.0 mg/dl (patients 5 < age =< 10 years of age)\r\n* 1.2 mg/dl (patients 10 < age =< 15 years of age)\r\n* 1.5 mg/dl (patients > 15 years of age)
+DONOR: Age >= 0.5 years
+Age (at the time of consent/assent): ?6 months to ?21 years
+Cohort 4 only: ?10 years to ?21 years
+If <12 years of age: Lanksy Performance Status >50%
+Age 18 - 80 years; age > 80 allowed at investigator discretion if performance status ? 1; and each organ system score ? 2 using cumulative illness rating scale (CIRS)
+Age ? 18 years or the minimum legal adult age (whichever is greater) at the time of Informed consent.
+Men and women ? 18 years of age
+18 years of age at the time of signing informed consent
+Subjects must be ?18 years of age.
+Subject must be ?18 years of age.
+Men and Women ? 18 years of age
+Patients must be > 24 months and < 30 years of age when registered on study.
+Patients must be > 2 years and < 30 years of age when registered on study.
+Women and men ?18 years of age with performance status of 0 or 1
+Patient must be ?18 years of age
+Participants who are newly diagnosed and not considered for high-dose chemotherapy due to: being age >=65 years; or participants less than (<) 65 years with presence of important comorbid condition(s) likely to have a negative impact on tolerability of high dose chemotherapy with stem cell transplantation. Sponsor review and approval of participants below 65 years of age is required before randomization
+Age 3 at the time of initial diagnosis to age 21 at the time of initial diagnosis
+Karnofsky (age ? 16 years) or Lansky (age < 16 years) performance status ? 50 at screening
+Demographics show age < 11
+Men and women ?18 years of age.
+Must be at least 18 years of age
+Men and women ? 18 years of age.
+Men and women: ? 65 years of age OR > 18 and < 65 years of age, provided that they meet at least one of the following criteria:
+Age ?18 years
+Age ?18 years.
+Men and women 18 to 85 years of age, inclusive.
+Age ? 13 years.
+Age at diagnosis at least 18 years.
+Age ? 18 years old
+Male, age 45 to 80 years
+Age ? 55 years and one year or more of amenorrhea
+Renal function defined as: A serum creatinine based on age/gender as follows: Maximum Serum Creatinine (mg/dL). Age Male Female 1 to < 2 years 0.6 0.6 2 to < 6 years 0.8 0.8 6 to < 10 years 1.0 1.0 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4 ? 16 years 1.7 1.4.
+Age 3 at the time of screening to age 21 at the time of initial diagnosis
+Karnofsky (age ? 16 years) or Lansky (age < 16 years) performance status ? 50 at screening.
+Be ?18 years of age;
+? 18 years of age.
+Age ? 18 years
+Women ? 18 and ? 75 years of age.
+The patient must be ?18 years of age
+Men and women ? 18 years of age.
+Patients must be ?18 years of age
+Age >= 70 years
+? 18 years of age
+Patients must be ? 18 years of age
+Age 18 years and above
+< 55 years of age
+Age (at the time of consent) ?18 years of age
+?45 years of age and has not had menses for over 2 years
+Age ? 18 years
+Age ? 18 years.
+Subject is ?18 years of age
+Age ?18 years at the time of screening
+Patients ?18 years of age;
+? 18 years of age
+Age >18 years
+At least 15 years of age Except: where local regulations and/or institutional policies do not allow for subjects < 18 years of age (pediatric population) to participate. For those sites, the eligible subject population is ? 18 years of age
+Men and women 18 years of age to 80 years of age of any ethnic origin or race at the time of signing the ICD.
+Age >21 years
+Have an ECOG performance status of 0-2 for ? 16 years of age and a Lansky performance status of 70-100 for < 16 years of age
+? 18 years of age.
+Age ? 18 years of age at the time of signing the informed consent document.
+Patients must be ? 18 years of age.
+Age ? 60 years
+Patients must be ? 18 years of age.
+Age ? 18 years.
+Age superior or equal to 18 years or country's legal age of majority if the legal age is superior to 18 years old.
+Age ? 60 years
+Men and women ? 18 years of age.
+Age ? 18 years
+At least 18 years of age
+Age
+Patients must be ? 12 months of age and ? 30 years of age at the time of study entry for patients diagnosed with DIPG.
+Patients must be ? 12 months of age and ? 21 years of age at the time of study entry for patients diagnosed with HGG.
+Patients 2-17 years of age must have a blood pressure that is ? 95th percentile for age, height and gender at the time of enrollment.
+Men ? 18 years of age at the time of informed consent.
+Age ? 50;
+Men & women ?20 years of age
+Age > = 18 years
+Age ?18
+? 18 years of age
+Adult women (? 18 years of age) with advanced TNBC.
+Age ? 18 years.
+Female, age ? 18 years
+Are at least 18 years of age at the time of informed consent
+Men and women ? 18 years of age
+Men and women ? 18 years of age
+At least 18 years of age
+All patients must be at least 18 years of age
+Age >= 18 years
+Age ? 18 years.
+Age ?18 years at the time of signing the informed consent document.
+Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
+Patients must be >/= 18 years of age.
+Subject is < 18 years of age.
+Patient of age between 50 to 75 years, inclusive.
+Age > 18 years at the time of consent.
+Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores 0, 1, or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
+Age ? 18 years old
+Age ? 18 years.
+Male or female, greater than or equal to (>=) 18 years of age (or having reached the age of majority according to local laws and regulations, if the age of majority is > 18 years of age); [i.e. >= 20 years of age in Japan])
+Age ? 15 years and < 71 years at the time of signing the informed consent form
+Subjects ? 18 years of age must have the ability to give informed consent according to applicable regulatory and local institutional requirements. Legal guardian permission must be obtained for subjects < 18 years of age. Pediatric subjects will be included in age appropriate discussion in order to obtain assent.
+Subject is ? 75 years of age.
+Be at least 55 years of age
+Patients must be ? 18 years of age.
+Lansky (age < 16 years at the time of assent/consent) or Karnofsky (age ? 16 years at the time of assent/consent) performance status ? 80 at screening
+Male or female patients age ? 18 years of age at the time of informed consent
+Age ?18 years.
+Patient is at least 18 years of age at randomization.
+Participant is ? 18 years of age at the time of signing the informed consent form.
+Women ? 18 years of age.
+Age ?18 years (? 20 years in Japan).
+Age: at least 20 years of age
+Female patients must have a bone age of equal to or greater than 12 years of age as determined by local read of appropriate radiographic imaging
+Male patients must have a bone age of equal to or greater than 14 years of age as determined by local read of appropriate radiographic imaging
+Cohort 1 patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\r\n* Note: patients in Cohort 1 will be stratified as follows:\r\n** Stratum 1: Patients >= 11 years of age but < 18 years\r\n** Stratum 2: Patients >= 11 years of age but < 50 years
+Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
+Men and women ? 18 years of age
+Age ? 18 years
+Men and women ? 18 years of age
+Age ?18 years.
+Age >/= 18 years
+Be ? 18 years of age on day of signing informed consent.
+Age ? 18 years.
+Men and women ? 18 years of age
+Age ? 18 years at the time of consent
+Adults ? 18 years of age.
+Age ?18 years;
+Patients must be ? 18 years of age.
+Age ?18 years
+Men and women ? 18 years of age.
+Age ?18 years
+Men and women ? 18 years of age
+Men and women ? 18 years of age.
+Age ? 18 years.
+Age at least 18 years.
+Men and women ? 18 years of age.
+Age ? 18 years.
+Subject must be ?18 years of age.
+Age greater than18 years
+? 18 years of age
+Male subjects of age ? 18 years
+Men and women, ages ? 18 years of age
+Age <18-years-old.
+?18 years of age.
+Age ? 18 years of age
+Age ?18 years.
+Serum creatinine =< 1.5 x the upper limit of normal for age, or calculated creatinine clearance or nuclear glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2\r\n* =< 0.6 mg/dL (1 to < 2 years of age)\r\n* =< 0.8 mg/dL (2 to < 6 years of age)\r\n* =< 1.0 mg/dL (6 to < 10 years of age)\r\n* =< 1.2 mg/dL (10 to < 13 years of age)\r\n* =< 1.4 mg/dL (females >= 13 years of age)\r\n* =< 1.5 mg/dL (males 13 to < 16 years of age)\r\n* =< 1.7 mg/dL (males >= 16 years of age)
+Age ?60
+Age 21 years or younger at the time of initial ALL diagnosis and age > 1 year at the time of study treatment initiation.
+Age ? 18 years (Age ? 12 years for patients with bone sarcomas).
+Age ? 18 years at the time of consent.
+Age: >=18 years of age at the time of providing informed consent.
+At least 18 years of age
+Minimum age in Japan is 20 years.
+Age ?18 years
+2 years to 21 years of age
+Serum creatinine based on age, or creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 50 ml/min/1.73m^2 (GFR >= 40 ml/min/1.73m^2 if < 2 years of age)\r\n* Maximum serum creatinine based on age\r\n** 0.8 mg/dL (=< 5 years of age)\r\n** 1.0 mg/dL (5 to =< 10 years of age)\r\n** 1.2 mg/dL (10 to =< 15 years of age)\r\n** 1.5 mg/dL (> 15 years of age)
+Age ? 18 years.
+Age >= 60 years and not candidates for conventional cytotoxic chemotherapy or refuse it; OR patients below the age of 60 years who are considered unfit and/or unable to tolerate standard chemotherapy at the discretion of the treating physician or the principal investigator
+Patients must be ? 18 years of age.
+Up to 65 years of age
+Age >= 18 years
+Age <18-years-old.
+Age > 18 years
+Age ?18 years.
+Male patients >/= 18 years of age
+? 18 years of age
+A serum creatinine based on age/gender as follows:\r\n* =< 0.6 mg/dL (for 1 to < 2 years of age)\r\n* =< 0.8 mg/dL (for 2 to < 6 years of age)\r\n* =< 1.0 mg/dL (for 6 to < 10 years of age)\r\n* =< 1.2 mg/dL (for 10 to < 13 years of age)\r\n* =< 1.4 mg/dL (for females >= 13 years of age)\r\n* =< 1.5 mg/dL (for males 13 to < 16 years of age)\r\n* =< 1.7 mg/dL (for males >= 16 years of age)
+? 18 years of age.
+Age < 18-years-old.
+Adult patient, >/= 18 years of age
+At least 18 years of age.
+Men or women ?18 years of age
+Males and female subjects ? 18 years of age at the time of enrollment, except in Japan where subjects must be ? 20 years of age at the time of enrollment
+Age >= 65years.
+Men & women ? 18 years of age
+DONOR: Age >= 18 years and =< 60 years
+Age 60-75 years at the time of diagnosis of AML
+Be at least 18 years of age
+Men & women ?18 years of age
+Men & women ?18 years of age
+Age > 21 years
+Subjects age ?18 years
+Age >/= 60 years
+DONOR: 18 to 75 years of age
+DONOR: At least 18 years of age
+>= 18 years of age
+Age of >/= 18 years.
+?18 years of age
+Patients ?18 years of age.
+Age ? 18 years of age
+Age > 60 years
+6 months to less than 18 years of age at the time of consent.
+Age at least 18 years at enrollment.
+Females 18 to 80 years of age
+Subjects younger than 18 years of age
+Age ?18 years
+Age > = 18 years at the time of signing the informed consent form.
+Age >= 18 years.
+Female gender and age ? 18 years at time of study entry
+Patients must be ? 15 years of age.
+DONOR: 14-75 years of age
+Age >=18 years at the time of consent.
+Age ?18
+At University of Oklahoma: age > 17 years old and =< 55 years for recipient
+18F FLT CANDIDATE TRANSPLANT RECIPIENT: Age >= 18 years old at National Cancer Institute (NCI), and age > 4 years and < 24 years at Children’s National Medical Center
+At least 18 years of age;
+E 05. Less than 18 years (or country's legal age of majority if the legal age is >18 years).
+Eighteen years of age or above
+Age >=18 years old
+Age > than 18 years at the time of signing the informed consent form.
+Women (regardless of menopausal status) or men ?18 years of age (or per local regulations).
+Unable to receive intensive chemotherapy regimens at enrollment, based on one of the following: I. Age ? 75 years, or II. Age < 75 years with at least 1 of the following co-morbidities:
+Age ?18 years.
+Age ?18 years.
+Age ? 12 years
+Male ?18 years of age.
+Be ? 18 years of age at time of consent
+Subjects 70 years of age or older; OR subjects 60-69 years of age who have one or more comorbidities.
+Age > 18 years
+Patients under the age of 18.
+For ESFT patients age ?12 years.
+For ESFT patients age ?12 years.
+Age ?18 years (non-ESFT candidates)
+Age >=18 years
+Age ? 65 years
+DONOR: Children less than 12 years of age.
+age ?40 years through ?85 years of age;
+Age ? 18 years
+Age < 3 years at time of diagnosis for all histological diagnosis
+Patients less than 3 years of age at diagnosis must meet one of the two following criteria:
+Age < 30 years
+Age >/= 18 years
+Age >= 16 years (age > 18 years to participate in optional symptom burden assessment)
+DONOR: Age < 12 years
+DONOR: Age less than 12 years
+Age ? 18 years
+Age ?18 years.
+Age ?18 years of age.
+Age 18 years.
+Women ? 18 years of age
+Age ? 18 years at the time of consent.
+Age ? 18 years at the time of consent
+?18 years of age
+Subject is 18 years of age or more at the time of signing the Informed Consent Form
+18 years of age.
+Minimum age 18 years (in certain territories, the minimum age requirement may be higher (e.g. 20 years in Japan and Taiwan)
+Men and women ? 18 years of age.
+Age ? 18 years.
+Karnofsky > 50% for patients > 16 years of age and Lansky > 50% for patients ? 16 years of age.
+Female subjects with age ? 18 years
+ECOG 0-2 or Karnofsky ? 50% for patients > 16 years of age; Lansky ? 50% for patients ?16 years of age.
+DONOR: Age < 60 years
+DONOR: Age: less than age 18 or older than age 60
+Age ? 18 years old.
+Age ? 18 years
+Men and women ? 18 years of age.
+>18 years of age.
+Female participants of non-childbearing potential, ?18 years of age
+Patients must be >18 years of age
+Age <18-years-old.
+Age >/= 18 years.
+Age ? 18 years old.
+? 6 months and < 25 years of age
+Subjects ? 16 years of age: Karnofsky ? 60% (Appendix A)
+Subjects < 16 years of age: Lansky scale ? 60% (Appendix A)
+Patients > 18 years of age must have the ability to give informed consent according to applicable regulatory and local institutional requirements. Legal guardian permission must be obtained for patients < 18 years of age. Pediatric patients will be included in age appropriate discussion in order to obtain assent
+Age >/= 18 years
+?18 years of age
+Subjects at least 18 years of age
+Age < 55 years old and > 4 months
+Age >=18 years (For subjects in Taiwan, Age >= 20 years)
+DONOR: age >= 18 years old
+Must be ?18 years of age
+MSC DONOR: age >= 18 years, =< 30 years
+Patients over 18 years of age, regardless of race of gender
+? 18 years of age.
+7. Age ?18 years.
+At least 18 years of age
+Male participants who are ?18 years of age
+Age ? 18 years.
+Age ? 18 years.
+Age > or = to 16 years
+Age >= 50 years and postmenopausal with no menses for at least one year prior to study enrollment
+Caregiver: Age >= 18 years
+Age ? 18 years
+Pediatric participants, 12 to 17 years of age inclusive
+Age >= 18 years.
+Age ? 18 years
+Age 8-16 years old at the time of consent
+Be ? 18 years of age on day of signing informed consent.
+Age ?21 years
+Age ? 18 years
+Age 19 years or older (age of consent in Nebraska); age 18 years or older (applicable to states where the age of majority is 18)
+Adult subjects; age ? 18
+Subjects ? 18 years age and ? 80 years of age at the time of signing the informed consent form.
+Patients younger than 15 years of age
+Age ?18 years.
+Age ?18 years
+Age ? 18 years;
+Patient is at least 18 years of age.
+Age ?18 years
+Patients ? 18 years of age.
+Age > or = to 21 years
+Age 18 to 70 years of age.
+?18 years of age.
+Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
+DONOR: At least 18 years of age
+At least 18 years of age.
+Age >/= 18 years
+Age ?18 years
+Age ?18 years
+Men and women ? 18 years of age
+Adult patients, >/= 18 years of age
+Age between 18 and 75 years old (both inclusive)
+12 < 18 years of age
+Patient must be ? 18 years of age.
+13 to 17 years of age inclusive at screening.
+Adult patients, >/= 18 years of age
+Patients must be ? 21 years of age at the time of enrollment.
+Karnofsky > 50% for patients > 16 years of age and Lansky > 50% for patients less than or equal to 16 years of age. (See Appendix I for Performance Scales).
+Age ? 18 years
+Age>18
+Age ? 18 years.
+Female, ?18 years of age
+Age >= 18 years
+Age >21 years
+At least 18 years of age.
+Age ? 18 years
+Age ? 18 years.
+Age ? 18 years.
+Age ? 18 years. .
+Age ? 18 years.
+Age ? 18 years
+Age ?21 years
+Age ? 18 years of age at the time of signing the Informed Consent Form.
+Subject must be ?18 years of age
+Participant’s age is 1 to 39 years, inclusive; (St. Jude participants must be aged 1 to 25 years)
+Be at least 18 years of age at the time of consent
+Age ?18 years.
+DONOR: At least 18 years of age
+Be at least 18 years of age
+Age ? 18 to ? 80 years at the time of signing the informed consent form
+At least 18 years of age
+Age >= 18 years
+Age: >3 months to <18 years of age.
+Age ? 18 years
+Age ? 18 years.
+Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
+Age ?18 years
+? 18 years of age
+At least 18 years of age at time of study entry
+At least 18 years of age
+Age ? 18 years of age, at the time of informed consent.
+Age <18 years.
+Men and women ?18 years of age
+Age >18 years of age.
+Age ?18 years
+? 18 years of age
+Age ?18 years
+Age >21 years
+? 18 years of age.
+Age between 18 and 75 years
+Age ? 18 years.
+Age >=18 years
+Adult patient, >/= 18 years of age
+Age ?18 years
+Age >=18 years
+Subject must be at least 18 years of age.
+Age 18 years or above
+Patients must be men and women >= 18 years of age.
+Adult participants, >/= 18 years of age
+Adult patients, >/= 18 years of age
+?18 years.
+Women ? 18 years of age
+Age >/=18 years old.
+Age 4 through 65 years
+Men and women ? 18 years of age
+Eighteen years of age or above
+-  Age >18 years.
+Is 0 months (at least 37 weeks gestation) to <18 years of age
+Age ? 18 years.
+Age ?12 years
+Age <18 years.
+Patients must be < 30 years of age when registered on study.
+Patients must have a life expectancy of at least 8 weeks and a Lansky (< 16 years age) or Karnofsky (> 16 years age) score of at least 50
+Age-adjusted serum creatinine 1.5 x normal for age/gender
+? 18 years of age
+Male or female between one month and <18 years of age (inclusive) at the time of signing the informed consent form (Part C and Part D between 12 months and <18 years of age, inclusive).
+For the initial dose escalation to identify the maximum tolerable or PK target dose, age between 2 years and <18 years (inclusive) at the time of signing the informed consent form. Children < 2 years of age will be enrolled once the age specific expansion cohorts are open.
+Age between 16
+Normal creatinine for age:\r\n* =< 0.8 mg/dL (age =< 5 years)\r\n* =< 1 mg/dL (age 6 to =< 10 years)\r\n* =< 1.2 mg/dL (age 11 to =< 15 years)\r\n* =< 1.5 mg/dL (age >= 16 years)\r\nOR
+Be ?18 years of age.
+Adults > 18 years of age
+DONOR: At least 18 years of age
+Age ? 18 years
+Adult patients, >/= 18 years of age
+Patients must be > 18 years of age
+Age of </= 18 years.
+Age 14-21
+Age ? 18 years of age
+Patient is ? 18 years of age on the day of consent signature
+Age and Reproductive Status
+At least 18 years of age
+Donor must be 18 to 70 years of age inclusive.
+Recipient must be 18 to 75 years of age inclusive.
+Age ? 18 years.
+18 years of age
+Age > or = to 18 years.
+Patient is ?18 years of age.
+Must be ? 18 years of age
+Age ?18 years
+Age ?18 years
+Age ? 18 years.
+Must be at least 18 years of age
+Age ?18 years.
+at least 18 years of age
+Must be at least 18 years of age
+Age ? 18 years
+Age > 18 years at the time of consent.
+Patients must be female at least 18 years of age.
+Patients above >= 65 years old should have an age-adjusted co-morbidity index of =< 3
+Age >/= 18 years.
+DONOR: Age 18 years to 80 years
+Participants must be < 31 years of age at the time of study entry\r\n* Participants currently on therapy at St. Jude, or within 3 years of completing therapy at St. Jude must be =< 24 years of age\r\n* Other participants must be =< 21 years of age
+Performance status: Karnofsky > 50% for >= 16 years of age; Lansky > 50% for children < 16 years of age
+The participant is age ? 18 years
+Patient is ? 15 and < 75 years of age.
+Performance status: Karnofsky >= 50 for > 10 years of age; Lansky >= 50 for children =< 10 years of age
+Age ? 18 years at the time of signing consent
+1 to < 18 years of age
+Performance status: Karnofsky ? 60% for 12 to <18 years of age; Lansky play scale ? 60% for 1 to < 12 years of age.
+Performance status - Lansky 30-100% (? 16 years of age)
+Patients must be greater than 18 years of age
+Age ? 18 years
+Age ? 18 to ? 80 years at the time of signing the informed consent form
+Creatinine clearance >= 70mL/min/1.73m^2 or serum creatinine based on age/gender as follows:\r\n* =< 0.4 mg/dl (age 1 month to < 6 months)\r\n* =< 0.5 mg/dl (age 6 months to < 1 year)\r\n* =< 0.6 mg/dl (age 1 year to < 2 years)\r\n* =< 0.5 mg/dl (age 2 years to < 6 years)\r\n* =< 1.0 mg/dl (age 6 years to < 10 years)\r\n* =< 1.2 mg/dl (age 10 years to < 13 years)\r\n* =< 1.4 mg/dl (females >= 13 years)\r\n* =< 1.5 mg/dl (males 13 years to < 16 years)\r\n* =< 1.7 mg/dl (males >= 16 years)
+Patients must be post-menopausal; post-menopausal will be defined as women meeting any of the following criteria:\r\n* >= 60 years of age; or\r\n* < 60 years of age and amenorrheic for >= 12 months prior to day 1 if uterus/ovaries are intact; or\r\n* < 60 years of age, and the last menstrual period 6-12 months prior to day 1, if intact uterus/ovaries and meets biochemical criteria for menopause (follicle-stimulating hormone [FSH] and estradiol within institutional standard for postmenopausal status); or\r\n* < 60 years of age, without a uterus, and meets biochemical criteria for menopause (FSH and estradiol within institutional standards for postmenopausal status); or\r\n* < 60 years of age and history of bilateral oophorectomy; surgery must have been completed at least 4 weeks prior to day 1; or\r\n* Prior radiation castration with amenorrhea for at least 6 months
+The parent must be at least 18 years of age to ensure the age of majority across all participating sites to legally consent their child
+15 to 39 years of age at diagnosis of first cancer
+Age 18 years or more
+Age ? 18 years at the time of screening.
+Subject is ?18 years of age at the time of signing the study informed consent.
+Karnofsky performance status >= 50% for patients >= 16 years of age and Lansky >= 50% for patients < 16 years of age
+Age ? 22
+Prostate cancer diagnosed at age =< 55 years
+PATIENT: >= 65 years
+Be over 18 years of age
+Age 18 years of age or older at last transplant
+The child is 3-8 years of age at time of enrollment
+One parent (? 18 years of age) can be present for all sessions
+EXCLUSION FOR PARENTS: Parent is < 18 years of age
+EXCLUSION FOR PARENTS: Patient is < 2 years of age, or > 24 years of age
+EXCLUSION CRITERIA FOR PATIENTS: Patient is < 2 years of age, or > 24 years of age
+Co-survivors must be over the age of 18 years
+PATIENTS: Age 30-89 years
+Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 OR a serum creatinine based on age/gender as follows:\r\n* =< 0.4 mg/dL (age 1 month to < 6 months)\r\n* =< 0.5 mg/dL (age 6 months to < 1 year)\r\n* =< 0.6 mg/dL (age 1 to < 2 years)\r\n* =< 0.8 mg/dL (age 2 to < 6 years)\r\n* =< 1 mg/dL (age 6 to < 10 years)\r\n* =< 1.2 mg/dL (age 10 to < 13 years)\r\n* =< 1.4 mg/dL (females age >= 13 years)\r\n* =< 1.5 mg/dL (males age 13 to < 16 years)\r\n* =< 1.7 mg/dL (males age >= 16 years)
+Child: child is age 5 to 17 years, 11 months
+Age\r\n* For centers that will use fluconazole as the antifungal comparator:\r\n** Age >= 3 months and < 21 years\r\n* For centers that will use voriconazole as the antifungal comparator:\r\n** Age >= 2 years and < 21 years
+Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
+For donors >= 18 years of age, ability to give informed consent
+Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
+Cancer diagnosis prior to 22 years of age, irrespective of current age
+Age >= 18 years
+Female, Age ?18 years.
+DONOR: Age >= 18 to =< 75 years old
+Patient refusal to participate (any age), or parental refusal to participate for patients less than 18 years of age
+Be at least 18 years of age
+Are between 55 and 85 years of age
+Age > 18 years at the time of consent.
+Karnofsky >= 50% for patients > 10 years of age and Lansky >= 50 for patients =< 10 years of age
+Is ?18 years or the minimum legal adult age (whichever is greater) and ?75 years (at Screening);
+For dose-escalation stage (tablets): age at study entry >= 6 years to < 18 years
+For dose-escalation stage (suspension): age at study entry >= 6 months to < 18 years. Participants <1 year of age will not be enrolled until >= 6 participants >= 1 year to < 18 years of age have received at least one cycle of therapy with suspension and until safety and pharmacokinetic assessment of these participants have been conducted.
+For expansion stage: age at study entry to be >= 6 months (>=6 years if suspension is not available) to < 30 years. Participants >= 6 months to < 1 year of age may not be enrolled until >= 6 participants >= 1 year to < 18 years of age have received at least one cycle of therapy with suspension in the dose-escalation phase and until safety and pharmacokinetic assessment of these participants have been conducted.
+Patients age ?60 years who:
+Any patient age ? 70 years.
+Patients age ?60 years who:
+Any patient age ? 75 years.
+Caregivers: At least 18 years of age
+Age ? 18 years
+Subjects must be at least 18 years of age
+Over age 18
+Age 5-17 years at time of study enrollment
+Subject is ?18 years of age.
+Under age 21;
+< 18 years of age
+DONOR: Age >= 18 years
+DONOR: Age < 18 years
+Bone Mineral Density (BMD) requirements: Osteopenia if under 70 years of age; Osteopenia or normal BMD if over 70 years of age
+Must be >= 18, but < 70 years of age with no matched 5/6 or 6/6 sibling donor - patients >= 70 and =< 75 years of age may be eligible if they have a Co-Morbidity score =< 2
+Age 40 years old to 74 years old
+Patient must have had a cancer diagnosis < 22 years of age, irrespective of current age
+Age ? 18 (or legal age of majority for sites outside US).
+Patients must be between 18 and 60 years of age
+Age >= 18 years
+RECIPIENT: Age 18 to 75 years
+Age >= 18 years and =< 70 years
+Age >= 18 years
+Age >= 18 years for the feasibility phase; age >= 10 years old AND >= 50 kg for the phase II portion
+Postmenopausal women, defined as:\r\n* Age > 45 with no menses for at least 2 years
+Patient is at least 18 years of age
+DONOR: Age >= 18 years
+DONOR: Age < 18 years
+Age ?18 and ?65 years
+Age > 75 years
+Must be >= 18, but < 70 years of age with no matched 7/8 or 8/8 sibling donor - patients >= 70 and =< 75 years of age may be eligible if they have a co-morbidity score =< 2
+Female age 18 to 55 years
+Age: 0-21 years at the time of diagnosis.
+Age: 0-21 years at the time of diagnosis.
+Subject must be female ? 40 years of age
+ECOG 0-1, or for children ?10 years of age, Lansky > 60
+Ability to give informed consent for patients greater than 18 years of age. For patients less than 18 years of age the legal guardian must give informed consent.
+? 18 years of age
+Age: 0-21 years at the time of diagnosis.
+?18 years of age at the time of signing informed consent
+Is 0 (at least 37 weeks gestation) to 17 years of age at time of randomization
+50 to 75 years of age
+At least 18 years of age
+Between 4.0 years and < 11.0 years of age at the time of recruitment
+Age ? 55 years and one year or more of amenorrhea
+Adult patients at least 18 years of age
+Patients with Lansky (age < 16 years) or Karnofsky (age >= 16 years) score < 50 will be excluded
+Karnofsky performance status >= 50 for patients >= 12 years of age; for children < 12 years of age, the Lansky play scale >= 50% can be substituted
+Individuals who are less than 18 years of age
+Signed document of assent obtained if child >= 10 years of age
+Karnofsky >= 70 for patients >= 16 years of age, and Lansky >= 70 for patients < 16 years of age
+Signed written informed consent (by parent if patient is < 18 years of age, or by patient, if he or she is >= 18 years of age)
+Patient assent for those >= 10 years of age and < 18 years of age for whom a parent provides informed consent
+Patients age ?18 years old
+Age 21-75 years at screening
+CHILD: Has a caregiver, >= 18 years of age that is willing to participate in the study
+PHASE I: Performance status >= 60 on Karnofsky scale for patients > 16 years of age and > 60 on Lansky scale for patients < 16 years of age
+EXPANSION COHORT: Performance status of >= 60 on Karnofsky scale for patients > 16 years of age and > 60 on Lansky scale for patients =< 16 years of age
+Age less than 18 years.
+Age < 18 years
+Female over 21 years of age;
+Age ? 18 years
+Patients must have a performance status of >= 50 using the Karnofsky scale for patients > 16 years of age and the Lansky scale for patients =< 16 years of age
+Age ? 18 years
+Age ?18 years.
+Age at treatment 1 to 35 years.
+Male or females with an age ? 18 years (? 20 years in Japan)
+Is at least 18 years of age at the time of consent
+Patients over the age of 18.
+Age > 18 years
+NORMAL VOLUNTEERS: Be >= 18 years of age
+Adult male >/= 18 years of age
+Age ? 18 years.
+Pediatric patients of any age are eligible, including those that may require sedation for MRI; more specifically, children 0-17 years of age and adults >= 18 years of age are eligible
+18 years of age or over.
+Participants must be at least 18 years of age
+Patients who are at least 18 years of age
+Age >/= 18 years
+Under 50 or over 74 years of age
+Adult patients over 18 years of age;
+Be age ? 18 years old.
+Be ? 18 years of age
+Age ? 18 years.
+Age: >1 month and <30 years at time of enrollment
+Age and Reproductive Status
+age 18+
+age ? 18 years
+Patients are men or women at least 18 years of age.
+?18 years
+Age > 65 years
+age >=18
+Age ? 18 years at time of consent (19 years if required by local or state laws)
+Age ? 18
+Patients must be >18 years-of-age.
+?18 years of age
+Patient is at least 18 years of age.
+Age ? 18 years
+Age ? 18 years